FDA Approves GLP-1 Obesity Pill Without Food or Water Restrictions
The US Food and Drug Administration (FDA) approved the oral glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron, marketed as Foundayo, for daily use in people with overweight or obesity. Unlike other oral GLP-1 drugs, orforglipron can be taken any time of day without food or water restrictions.
Original Source
Read the full article at Jamanetwork →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.